Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.
The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.

The global Myasthenia Gravis Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Myasthenia Gravis Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myasthenia Gravis Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Myasthenia Gravis Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Myasthenia Gravis Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Flamel Technologies
Roche
Grifols
Pfizer
Shire
Novartis
Valeant
Alexion
Catalyst
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins

Segment by Application
Hospitals
Clinics